Small bowel obstruction following computed tomography and magnetic resonance enterography using psyllium seed husk as an oral contrast agent

Yingming Amy Chen MD1, Patrick Cervini MD2, Anish Kirpalani MD1, Paraskevi A Vlachou MD1, Samir C Grover MD MEd3, Errol Colak MD1

The authors report a case series describing four patients who developed small bowel obstruction following the use of psyllium seed husk as an oral contrast agent for computed tomography or magnetic resonance enterography. Radiologists who oversee computed tomography and magnetic resonance enterography should be aware of this potential complication when using psyllium seed husk and other bulking agents, particularly when imaging patients with known or suspected small bowel strictures or active inflammation.

Key Words: CT enterography; MR enterography; Oral contrast

CT Enterography (CTE) and magnetic resonance enterography (MRE) play an increasingly critical role in the diagnosis, assessment and management of patients with small bowel disease. CTE and MRE have largely replaced fluoroscopic examinations, such as small bowel follow-through and enteroclysis, by providing accurate characterization of the bowel wall and visualization of disease beyond the bowel wall (1-3). Furthermore, CT enterography (CTE) and MRE provide a more comfortable patient experience by circumventing the need for nasojejunal intubation (4).

The diagnostic accuracy of CTE and MRE is predicated on adequate distension of the small bowel by oral contrast. Multiple oral contrast options are available, including psyllium seed husk, which is a nondigestible bulk fibre laxative. To date, there is no established consensus on the ideal oral contrast agent for CTE and MRE.

We report three cases of small bowel obstruction following CTE at Windsor Regional Hospital (Ouellette Campus, Windsor, Ontario) and one case following MRE at St Michael’s Hospital (Toronto, Ontario) with psyllium seed husk (Metamucil, Proctor & Gamble, USA) as the oral contrast agent.

**EXAMINATION PROTOCOL**

**CTE protocol**
Patients were instructed to be nil per os from midnight and to arrive 1 h before the examination. Three doses of oral contrast were prepared by diluting 15 mL Metamucil in 450 mL of water. Patients were instructed to drink 450 mL of oral contrast 60 min, 40 min and 20 min before the examination.

**MRE protocol**
Patients were instructed to be on a clear liquid diet after 17:00 the day before the examination, to take an enema (Fleet, CB Fleet, USA) the morning of the examination, and to arrive 2 h before the examination. Patients were administered 10 mg metoclopramide orally before drinking the Metamucil solution to promote peristalsis. Metamucil at a dose of 1.6 g/kg was diluted in 2000 mL of water. Patients were instructed to drink 500 mL every 30 min. An additional 10 mg of metoclopramide was administered after drinking 1000 mL of oral contrast to ensure adequate transit of oral contrast into the small bowel.

**Case 1**
A 55-year-old woman underwent CTE for the assessment of Crohn disease. CT demonstrated active disease involving 20 cm of the distal ileum characterized by bowel wall thickening, mucosal hyperenhancement, mural stratification, significant luminal narrowing and mesenteric inflammation (Figure 1A). Approximately 6 h after CTE, she presented to the emergency department with diffuse abdominal pain. Abdominal radiographs performed 9 h after CTE demonstrated dilated small bowel with air-fluid levels (Figure 1B). The patient was admitted overnight for conservative treatment and discharged the next day following resolution of symptoms.

**Case 2**
An 88-year-old man underwent CTE to rule out a small bowel cause of anemia. No small bowel abnormalities were demonstrated by CTE. The patient developed progressively worsening abdominal pain in the...
hours that followed the examination and returned to hospital the next morning. Abdominal radiographs were consistent with a small bowel obstruction (Figure 2). The patient improved with conservative management and his symptoms resolved by the next day.

Case 3
A 61-year-old woman with a presumed history of ulcerative colitis and remote total colectomy underwent CTE for symptoms of intermittent bowel obstruction. The patient was treated conservatively for a small bowel obstruction three weeks earlier. CTE revealed a right lower quadrant parastomal hernia with active inflammation of the immediately upstream small bowel (Figures 3A and 3B). The remainder of the small bowel was unremarkable. The patient presented 10 h later with generalized abdominal pain and nausea. Repeat CT scan of the abdomen showed diffuse small bowel dilation with a transition point at the parastomal hernia (Figures 3C and 3D). The patient did not improve with conservative management and exploratory laparotomy was undertaken the next day. Multiple adhesions were found around the stoma that resulted in kinking of the adjacent bowel. An ischemic segment of bowel was resected and a new stoma was created. There were no perioperative complications and the patient was discharged in stable condition.

Case 4
A 51-year-old man with a history of Crohn disease and distal ileal resection underwent MRE that demonstrated a long segment of narrowing of the efferent limb of the side-to-side ileocolic anastomosis...
There were no imaging features to suggest active small bowel inflammation. Approximately 12 h after the examination, the patient developed severe nausea and vomiting, diffuse abdominal pain and bloating. A CT scan of the abdomen demonstrated a high-grade small bowel obstruction with a transition point just beyond the site of the ileoileal anastomosis at the narrowed segment of the efferent limb (Figure 4B). He was managed conservatively by nasogastric intubation and bowel rest. His symptoms resolved completely by 48 h.

DISCUSSION

CTE and MRE have emerged as important investigations for small bowel disorders (2,3), and in influencing clinical management of Crohn disease (5,6). Established indications for CTE and MRE include staging and follow-up of inflammatory bowel disease and its complications, evaluation of obscure gastrointestinal bleeding and investigation of small bowel tumours (7). Emerging uses include evaluation of diffuse small bowel diseases, such as celiac disease (8) and vasculitis, as well as screening of strictures before capsule endoscopy (9). The added advantages of MRE include improved tissue contrast and lack of ionizing radiation, making it ideal for younger patients with inflammatory bowel disease who often require repeated cross-sectional imaging. Furthermore, MRE is capable of real-time functional imaging, which assesses small bowel peristaltic patterns in gastrointestinal motility disorders (10).

Bowel distension is essential for small bowel imaging because collapsed bowel may mimic or obscure small bowel pathology. To date, there is no established consensus on the ideal oral contrast agent for CTE and MRE. Multiple oral contrast agents are available, with the choice varying among institutions based on extent of bowel distension, uniformity of luminal opacification, availability, ease of use, cost and side-effect profile. CTE and MRE oral contrast agents are either hyperosmolar agents that prevent the absorption of water from the small bowel or bulking agents that result in small bowel distension.

The most commonly used oral agents are polyethylene glycol and low-density barium suspensions such as VoLumen (Bracco Diagnostics, USA) with mannitol, sorbitol, methylcellulose, locust bean gum and bulk fibre laxatives representing less commonly used options (11).

While VoLumen is a commonly used oral contrast agent in many jurisdictions, it has not been approved by Health Canada (the Canadian drug regulatory agency) for use as an oral contrast agent. We have anecdotally observed variable small bowel distension and gastrointestinal tract transit time when using polyethylene glycol as an oral contrast agent. Small bowel obstruction following use of psyllium is an uncommon occurrence. Only two cases of small bowel obstruction have been reported after CTE or MRE when using Metamucil or a psyllium-equivalent oral laxative.

Psyllium seed husk products, including Metamucil, are commonly used bulking laxative and fibre supplement products. When mixed with water, psyllium can function as an oral contrast agent by forming a nondigestible hydrogel that absorbs water and subsequently distends the small bowel (12). It is relatively inexpensive, easy to prepare and administer, and well-tolerated by patients. Reported side effects are typically mild and include bloating, flatulence and diarrhea (13). The reported experience of other centres (12) supported its performance and safety as an oral contrast agent. Consequently, Metamucil was being used as the oral contrast agent for CTE at Windsor Regional Hospital (Ouellette Campus) and MRE at St Michael's Hospital.
active inflammation. For centres that continue to use psyllium or other bulking agents, patients should be informed of the potential risk of obstruction and of symptoms that should prompt them to seek medical attention. Metamucil has been replaced by a 3% sorbitol solution for both CTE and MRE examinations at our institutions, with no negative impact on small bowel distension (25), patient acceptance and side effects, or departmental workflow.

CONCLUSION

We report a case series describing four patients who developed small bowel obstruction following the use of psyllium seed husk (Metamucil) as an oral contrast agent for CTE or MRE. Radiologists who oversee CTE and MRE examinations should be aware of the potential complication of Metamucil and other bulking agents, particularly when imaging patients with known or suspected small bowel strictures or active inflammation.

DISCLOSURES: The authors have no financial disclosures or conflicts of interest to declare.

REFERENCES

Psyllium seed husk as an oral contrast agent


